Kite (Gilead) and Arcellx Report the Expansion of its Collaboration Agreement for CART-DdBCMA in Multiple Myeloma
- Kite and Arcellx have expanded their Dec’22 collaboration agreement to co-develop & co-commercialize Arcellx’s CART-ddBCMA as a treatment for r/r multiple myeloma
- The expansion was made to include lymphomas as an indication for CART-ddBCMA. Moreover, Kite exercised its option to license ACLX-001, Arcellx’s ARC-SparX program, for the treatment of multiple myeloma
- Upon closing of the transaction (expected by YE 2023), Arcellx will receive an up front equity investment of $200M at $61.68/share to purchase 3,242,542 shares of its common stock along with non-dilutive cash payment of $85M & will be eligible for potential milestone payments
Ref: Businesswire | Image: Kite
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at email@example.com.